Liposomal bupivacaine in posterior spine surgery: A piece of the puzzle for postoperative pain
Article History
-
Received: ,
Accepted: ,
Abstract
Abstract
Liposomal bupivacaine (LB) is a local analgesic that may be used at the time of surgery to limit postoperative pain around the surgical site. Its efficacy in decreasing pain, decreasing narcotic consumption, decreasing length of stay, and improving mobility is an area of intense research. The purpose of this study was to determine whether LB use was associated with improved patient-reported pain scores in the first 72 h following posterior spinal surgery, decreased postoperative narcotic need, and decreased length of stay.
One hundred and five patients undergoing elective posterior cervical or lumbar surgery were included in retrospective analysis. Forty-eight patients who received LB intraoperatively were compared with a historical cohort of 56 patients who underwent similar procedures and did not receive postsurgical infiltration with local analgesia. The same pain medication protocol was utilized postoperatively.
Demographics, clinical characteristics, and total morphine milligram equivalents did not differ significantly between the groups. The treatment group averaged a decreased length of stay (1.85 days treatment, 2.68 days control, p = 0.057). Treatment with LB was associated with lower pain levels at 24 h (5.2 treatment, 6.4 control, p = 0.04) and 48–72 h (4.9 treatment, 6.6 control, p = 0.007) after surgery.
LB improved patient perception of pain in the acute postoperative time period.
Intraoperative LB injection, coupled with focused early mobilization efforts and multimodal pain control, may lead to improved patient-reported outcomes, shorter length of stay, and decreased risk of perioperative complications.
Keywords
This article was originally published by Reed Elsevier India Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
1 Introduction
In the wake of the opioid epidemic, the need for reliable, non-narcotic pain management for the post-surgical patient has been well established. One such medication includes liposomal bupivacaine (LB). LB (tradename EXPAREL, Pacira Pharmaceuticals, Parsippany, New Jersey) is a formulation consisting of bupivacaine and a lipophilic carrier, which is designed to elute a steady, prolonged release of medication into the surrounding tissues up to 72–96 h from the time of administration.1 This medication aims to be a potential remedy for the increasing narcotic needs of patients after orthopedic procedures and has been studied in patients undergoing surgeries of the hip, shoulder, knee, spine, and foot and ankle.1–7
Early studies on LB demonstrated promising results, including decreased postoperative opioid consumption, fewer adverse medication effects, decreased length of stay, less time using patient-controlled analgesia pumps, and higher patient satisfaction scores.1,7–10 Several of these studies have the potential for reporting bias due to conflicts of interest and industry sponsorship. Other studies have demonstrated contradicting results, such as no change or worsened patient-reported pain in comparison to similar modalities.6,8,11–16 Additionally, LB represents a significant increase in cost compared with that of traditional local anesthetic. Whether LB adds value to patients’ perioperative care necessitates careful consideration.
In light of these conflicting findings, we sought to determine the clinical utility of LB at our own institution. We examined whether 1) LB use was associated with improved patient-reported pain scores in the first 72 h after posterior spinal surgery, 2) whether LB use was associated with decreased postoperative narcotic need, and 3) whether LB use was associated with an overall decreased length of stay in the hospital.
2 Methods
2.1 Study design and setting
After institutional review board approval, a retrospective chart review was conducted of patients who underwent elective posterior spine surgery of the cervical and lumbar spine at a single institution. The study was conducted through the Veterans Administration Health System and primarily included elderly males.
One hundred and four patients were included in the analysis. Forty-eight patients were included in the treatment group and received an LB injection during wound closure according to the manufacturer's recommendations. The remaining 56 patients were in the non-treatment group and did not receive LB intraoperatively. Inclusion criteria were (1) posterior lumbar spine decompression and/or fusion, or (2) posterior cervical spine decompression and/or fusion performed primarily for degenerative pathology of the spine. Exclusion criteria were (1) thoracic spine surgery, (2) patients with hypersensitivity reactions to local anesthesia, (3) patients with pathology of neoplastic/infectious origin, and (4) anterior-approach spine surgery.
2.2 Intervention technique
All patients in the treatment group received 266 mg (20 ml) of liposomal bupivacaine as per the manufacturer's instructions on dosing. Patients undergoing single-level decompression or decompression with fusion were directly injected with 20 ml of the concentrated form of LB. For patients undergoing two- or three-level spinal procedures, 20 ml of LB was diluted with 20 ml of the preservative-free normal saline per the manufacturer's instructions. For patients undergoing procedures of four or more levels, LB was diluted with 40 ml of normal saline to make a total volume of 60 ml. Half of the total volume was injected in the paraspinal muscles along the length of the incision in small aliquots of approximately 2 ml throughout the wound. The remaining half of the volume was injected into the subcutaneous tissue along the length of the incision in a similar fashion. A subfascial drain was placed in all patients who underwent a lumbar or cervical fusion. In patients undergoing decompression only, the decision to drain the wound was made based on the status of local hemostasis. Commonly, those with single or two-level decompressions were treated without a drain, while the majority of patients with three-level decompressions had a drain placed. Postoperatively, opioid-naïve patients were prescribed oral oxycodone and acetaminophen 5/325 mg 1–2 tablets every 4 h based on a pain scale, with intravenous morphine 2–6 mg every 2 h based on a pain scale for breakthrough pain. Patients receiving chronic opioids preoperatively were maintained on their same dosages of medication postoperatively, with additional breakthrough pain medications available as needed.
2.3 Measures
Patient factors collected included Body Mass Index (BMI), history of diabetes mellitus (Y/N), cigarette smoking status (Y/N), presence or absence of preoperative opioid intake for longer than two consecutive weeks in the twelve months preceding surgery, and history of major depressive disorder or PTSD. Intraoperative data collected consisted of surgical location (cervical/lumbar), number of spinal levels (1, 2, 3+), the specific procedure performed, fusion procedure (Y/N), and dose of LB for the treatment group. Postoperative data were collected in the postoperative anesthesia care unit using a numeric pain rating scale, and consisted of immediate postoperative pain, pain scores at 6 h, pain scores at 24 h, and pain scores at 48–72 h, when available. Pain levels was collected from nursing records. Our hospital follows a standardized protocol for collection of postoperative patient outcomes. A numerical pain scale is used to assess pain levels in which a numerical scale (1-10) is used with representative pictures to gauge pain. The pain level is self-reported by the patients, and as the scale is standardized, this removes heterogeneity from its collection. Intravenous (IV) and oral opioid medication consumption in the first 24 h after surgery were collected and quantified into morphine milligram equivalents (MME). The length of hospital stay was abstracted from the medical record.
2.4 Outcome measures
Postoperative patient-reported pain, length of hospital stay, and total MME required for pain control were compared between LB patients and controls. A subgroup analysis of the LB cohort was performed to assess for any influence of patient characteristics or medical comorbidities on the postoperative outcomes. Factors analyzed were BMI, preoperative opioid use, cigarette smoking status, history of psychological disorder and anatomic region operated (lumbar vs. cervical).
2.5 Statistical analysis
Descriptive statistics were used to summarize the patient and clinical characteristics between the treatment and control groups. Means (with standard deviations) were calculated for continuous measurements and comparisons were made with a t-test. Counts and percentages were calculated for categorical measurements and comparisons were made with Chi-square tests. A repeated measures analysis of variance was performed to compare the pain levels between the two groups across the four time points (immediately after surgery, 6 h after surgery, 24 h after surgery, 48 or 72 h after surgery). t-tests and an ANOVA were used to compare the average MME consumption in the treatment group for each categorical variable. A regression analysis was performed to compare the average MME consumption in the treatment group for each continuous variable. Two participants in the treatment group had incomplete MME records and were excluded from subgroup analysis.
3 Results
In bivariate analysis, demographics, preoperative clinical characteristics, fusion procedure, and total MME did not differ significantly between the treatment and control groups. LB treatment was associated with decreased patient-reported pain scores at 24, 48, and 72 h after surgery (5.2 vs 6.4 at 24 h, p = 0.042; 4.9 vs. 6.6 at 48–72 h, p = 0.007 [Table 1; Fig. 1]). Hospital length of stay in the treatment group was noted to be lower on average (1.8 vs. 2.7, p = 0.057) and trending towards significance. Total MME did not differ significantly between the two groups (44 vs. 54, p = 0.21).
| Treatment (N = 48) | Control (N = 56) | Total | pa | |
| Preop opioids >6 mo, n(%) | 19 (40) | 29 (52) | 48 (46) | .21 |
| BMI, mean (std) | 31 (4.3) | 31 (5.9) | 31 (5.2) | .80 |
| DM, n(%) | 15 (31) | 24 (43) | 39 (38) | .22 |
| Smoking, n(%) | 17 (35) | 19 (34) | 36 (35) | .87 |
| History of depression/PTSD, n(%) | 22 (46) | 24 (43) | 46 (44) | .76 |
| Site of procedure, n(%) | ||||
| Cervical | 10 (21) | 7 (13) | 17 (16) | .25 |
| Lumbar | 38 (79) | 49 (88) | 87 (84) | |
| Fusion, n(%) | 24 (50) | 34 (61) | 58 (56) | .273 |
| Immediate pain level, mean (std) | 3.3 (3.2) | 4.1 (3.2) | 3.8 (3.2) | .20 |
| Pain level post 6 h, mean (std) | 5.8 (2.6) | 6.6 (2.0) | 6.3 (2.3) | .094 |
| Pain level post 24 h, mean (std) | 5.2 (2.9) | 6.4 (2.3) | 5.9 (2.6) | .042 |
| Pain level post 48/72 h, mean (std) | 4.9 (2.9) | 6.6 (2.2) | 5.9 (2.6) | .007 |
| Hospital stay (days), mean (std) | 1.8 (2.0) | 2.7 (2.4) | 2.3 (2.2) | .057 |
| MME, mean (std) | 44 (45) | 54 (38) | 49 (42) | .21 |

In a bivariate analysis, there was no significant difference between demographics, clinical characteristics, hospital stay, total MME, and pain levels in patients undergoing either lumbar or cervical spine surgery (Table 2).
| Cervical (N = 17) | Lumbar (N = 87) | Total | pa | |
| Preop opioids >6 mo, n (%) | 7 (41) | 41 (47) | 48 (46) | .65 |
| BMI, mean (std) | 29 (5.1) | 32 (5.2) | 31 (5.2) | .14 |
| DM, n (%) | 3 (18) | 36 (41) | 39 (38) | .065 |
| Smoking, n (%) | 9 (53) | 27 (31) | 36 (35) | .083 |
| History of depression/PTSD, n (%) | 6 (35) | 40 (46) | 46 (44) | .42 |
| Fusion, n(%) | 13 (76) | 45 (52) | 58 (56) | .060 |
| Dose of LB (cc), n (%) | ||||
| 0 | 7 (41) | 49 (56) | 56 (54) | . 25 |
| 20 | 10 (59) | 38 (44) | 48 (46) | |
| Immediate pain level, mean (SD) | 3.5 (3.1) | 3.8 (3.2) | 3.8 (3.2) | .72 |
| Pain level post 6 h, mean (SD) | 7.0 (1.6) | 6.1 (2.4) | 6.3 (2.3) | .17 |
| Pain level post 24 h, mean (SD) | 6.3 (2.2) | 5.8 (2.7) | 5.9 (2.6) | .56 |
| Pain level post 48/72 h, mean (SD) | 6.5 (2.1) | 5.8 (2.7) | 5.9 (2.6) | .41 |
| Hospital stay (days), mean (SD) | 3.0 (2.8) | 2.2 (2.1) | 2.3 (2.2) | .15 |
| MME, mean (SD) | 60 (34) | 47 (43) | 49 (42) | .27 |
In subgroup analysis of the treatment group, participants with diabetes required less MME than did those without diabetes (26 vs. 52 MME, p = 0.04 [Table 3]). Those who underwent fusion procedures required significantly more average MME (65 vs 21, p = 0.0005).
| N | Mean MME (SD) | p-value | |
| Preop opioids >6 mo | |||
| No | 27 | 35 (38) | 0.14 |
| Yes | 19 | 55 (53) | |
| BMI Categories | |||
| <18.5 kg/m2 | 0 | 0.33 | |
| 18.5–24.9 kg/m2 | 3 | 38 (38) | |
| 25–29.9 kg/m2 | 15 | 58 (54) | |
| ≥30 kg/m2 | 28 | 36 (40) | |
| DM | |||
| No | 31 | 52 (50) | 0.04 |
| Yes | 15 | 26 (30) | |
| Smoking | |||
| No | 29 | 43 (49) | 0.86 |
| Yes | 17 | 45 (41) | |
| History of depression/PTSD | |||
| No | 25 | 41 (50) | 0.64 |
| Yes | 21 | 47 (40) | |
| Site of procedure | |||
| Cervical | 10 | 64 (42) | 0.11 |
| Lumbar | 36 | 38 (45) | |
| Fusion | |||
| No | 22 | 20.52 (29.9) | 0.0005 |
| Yes | 24 | 64.58 (47.5) | |
Regression analysis was used to compare total MME and patient-reported pain score at various points in time. At 24 h post-surgery, the total MME required increased by 5.5 for every one-point increase in pain score (p = 0.03 [Fig. 2]), meaning that a patient who rated their pain as 6 out of 10 at 24 h post-surgery would ultimately receive 5.5 MME more during their hospital stay than would a patient who rated their pain 5 out of 10 at the same time point. A similar regression analysis was completed comparing MME and hospital length of stay. On average, MME increased by 8 for every 1 extra day in the hospital (p = 0.01 [Fig. 3]).


We had no notable complications relating to the use of local anesthetic either during the observation period for this study or during long-term follow up.
4 Discussion
Multiple studies have demonstrated that spinal surgery is a high-risk event for persistent opioid use with prevalence rates ranging from 4 to 26% in opioid-naive patients.17–20 Additionally, patients with preoperative opioid dependence fail to discontinue the use of opioids after surgery, even when the opioids prescribed are for conditions addressed by the spinal surgery.17,19 In light of these findings, multimodal pain regimens, including non-narcotic medicines, may limit postoperative narcotic consumption and prevent opioid dependence.
The finding that intraoperative treatment with LB was associated with lower patient-reported pain scores one to three days after surgery is significant, as this represents the time when patients are mobilizing with physical therapy and recovering functionality. There is a growing body of evidence supporting the benefits of early mobilization after elective spine surgery. Early mobilization can be defined as ambulation within 24 h of surgery. Benefits of this approach include improved patient-reported outcomes and engagement with therapy, decreased length of stay, and fewer postoperative complications.21–24 Though there was no statistically significant difference in hospital length of stay in the present study, the treatment group had, on average, a shorter length of stay that trended toward significance, which correlates with prior studies demonstrating this finding.16 It should be noted that findings of reduced pain and shortened length of stay have not been consistently reproducible in other LB studies.11–13 Postoperative protocols included in these studies are highly variable and therefore make comparison difficult.
It is interesting that while the treatment group had lower pain levels at certain points postoperatively, there were no significant differences in MME between the two groups. This highlights the fact that pain perception is multifactorial and past experiences, outcome expectations as well as psychosocial circumstances could potentially affect consumption of analgesics. Prior research has demonstrated a correlation between patient expectations of pain relief following surgery and clinical outcome at short-term follow up.25 The relationship may exist between expectations and immediate pain perceptions also, but has not been investigated to our knowledge.
Still, the need for consistent postoperative pain management strategies in patients undergoing elective spine surgery remains. To address this need, many institutions are implementing Early Recovery After Surgery (ERAS) programs for elective spinal surgery. These programs emphasize the importance of multimodal pain control and early mobilization following surgery, and have demonstrated improved cost-effectiveness and decreased opioid consumption, especially when combined with LB.26,27 A team approach is taken to pain control and consists of preadmission counseling on expected recovery, local analgesia with liposomal bupivacaine, minimizing drain usage, and multimodal pain regimens. This includes gabapentin, tramadol, and acetaminophen.28 Based on our results, we hypothesize that the combination of LB with the principles of ERAS may produce a synergistic effect in limiting complications associated with narcotic use and immobilization, and decreasing the overall length of hospitalization.
It is widely accepted that patients requiring fusion procedures have significantly higher postoperative pain than those undergoing decompression only. This is likely secondary to the wider necessary exposure, increased muscle dissection, and longer times of retraction necessitated by fusion procedures. Our study demonstrated that this difference persisted despite LB administration in the treatment group as evidenced by the increased MME requirements in the fusion subgroup.
The observation that patients with diabetes required fewer total MME in the postoperative period than did those without diabetes is an interesting finding. Multiple studies have indicated that patients with diabetes who undergo spine surgery have consistently worse outcomes in regards to pain than do those without diabetes.29–31 However, these studies did not evaluate specifically for differences in acute postoperative pain. It is uncertain whether our differences were due to unknown confounding variables or a true impact of diabetes mellitus. One of the plausible explanations for this difference is altered sensory perceptions due to underlying subclinical or overt peripheral neuropathy; however, the exact mechanism is unclear.
The findings that increased patient-reported pain levels at 24 h were associated with increased total MME and that increased length of stay was associated with increased MME may appear to be obvious. However, these findings are significant, as greater emphasis is continually placed on decreasing the total MME prescribed to patients, while maintaining adequate analgesia and mobilization. While there was no statistically significant difference in the total MME given to patients who received intraoperative LB injection in the present study, these patients consistently reported lower pain levels at the time of discharge and, on average, stayed in the hospital for a shorter time. We postulate that these factors may lead to less reliance on opioid pain control at the time of discharge and therefore a decreased likelihood for chronic opioid dependence.
Our study was subject to limitations. First, the nonrandomized design of the study lends itself to misclassification bias. Second, the retrospective nature of this study is inherently prone to selection and recall bias. Third, the small sample size and relatively specific nature of our patient population may limit the generalizability of our results and makes the results susceptible to type II error. Finally, the subjective nature of the perception of pain limits our ability to objectively quantify the postoperative experience of our participants uniformly. Nonetheless, the findings serve as valuable additional data on a novel medication with lack of clear benefits. Subgroup analysis based on patient characteristics improves our understanding of these factors to guide careful patient selection.
5 Conclusions
In our cohort, LB improved patient perception of pain in the acute postoperative time period. We believe that LB can be a useful tool in decreasing pain and facilitating early mobilization in patients after posterior spinal surgery. Intraoperative LB injection, coupled with focused early mobilization efforts and multimodal pain control, may lead to improved patient-reported pain control and shorter length of stay. Future prospective randomized control trials incorporating LB and ERAS in patients undergoing posterior spinal surgery may help clinicians create standardized perioperative protocols aimed at reducing opioid dependence and facilitating early mobilization after surgery.
Funding
This research did not receive a specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
The Authors (DF, HM, CS, NK) certify that they and any members of their immediate families, have no commercial associations (such as consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.
Institutional ethical committee approval
This study received Institutional Review Board approval from the Oklahoma Veterans Administration. IRB No. 12427.
Authors contribution
D. Alex Forrester: Data curation, formal analysis, investigation, methodology, project administration, validation, writing – original draft, writing – review and editing.
Harrison Miner: investigation, validation, writing – original draft, writing – review and editing.
Cameron Shirazi: data curation, methodology, project administration.
Niranjan Kavadi: Conceptualization, investigation, methodology, review & editing, supervision.
References
- A phase 3, randomized, placebo-controlled trial of DepoFoam(R) bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011;28:776-788.
- [Google Scholar]
- Continuous posterior lumbar plexus nerve block versus periarticular injection with ropivacaine or liposomal bupivacaine for total hip arthroplasty: a three-arm randomized clinical trial. J Bone Joint Surg Am. 2017;99:1836-1845.
- [Google Scholar]
- Comparison of liposomal bupivacaine infiltration versus interscalene nerve block for pain control in total shoulder arthroplasty: a meta-analysis of randomized control trails. Medicine (Baltim). 2017;96
- [Google Scholar]
- Periarticular injection after total knee arthroplasty using liposomal bupivacaine vs a modified ranawat suspension: a prospective, randomized study. J Arthroplasty. 2016;31:633-636.
- [Google Scholar]
- Liposomal bupivacaine: a comparative study of more than 1000 total joint arthroplasty cases. Orthop Clin N Am. 2015;46:469-477.
- [Google Scholar]
- Liposomal bupivacaine versus traditional periarticular injection for pain control after total knee arthroplasty. J Arthroplasty. 2014;29:1687-1690.
- [Google Scholar]
- A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee. 2012;19:530-536.
- [Google Scholar]
- Liposomal bupivacaine incisional injection in single-level lumbar spine surgery. Spine J. 2016;16:1305-1308.
- [Google Scholar]
- Improving total knee arthroplasty perioperative pain management using a periarticular injection with bupivacaine liposomal suspension. Arthroplast Today. 2016;2:37-42.
- [Google Scholar]
- Does subcutaneous infiltration of liposomal bupivacaine following single-level transforaminal lumbar interbody fusion surgery improve immediate postoperative pain control? Asian Spine J. 2018;12:85-93.
- [Google Scholar]
- Can liposomal bupivacaine Be safely utilized in elective spine surgery? Global Spine J. 2019;9:133-137.
- [Google Scholar]
- The efficacy of liposomal bupivacaine in lumbar spine surgery. Int J.Spine Surg. 2018;12:434-440.
- [Google Scholar]
- Does local administration of liposomal bupivacaine reduce pain and narcotic consumption in adult spinal deformity surgery? Global Spine J. 2021;11:896-902.
- [Google Scholar]
- Use of liposomal bupivacaine in the postoperative management of posterior spinal decompression. J Neurosurg Spine. 2016;25:88-93.
- [Google Scholar]
- Retrospective assessment of the use of liposomal bupivacaine in lumbar fusions in immediate postoperative hospital care. World Neurosurg. 2020;141:e820-e828.
- [Google Scholar]
- Intramuscular liposomal bupivacaine decreases length of stay and opioid usage following lumbar spinal fusion. Clin Spine Surg. 2020;33:E359-E363.
- [Google Scholar]
- Benchmarks of duration and magnitude of opioid consumption after common spinal procedures: a database analysis of 47,823 patients. Spine (Phila Pa 1976). 2019;44:1668-1675.
- [Google Scholar]
- Incidence and risk factors for chronic postoperative opioid use after major spine surgery: a cross-sectional study with longitudinal outcome. Anesth Analg. 2018;127:247-254.
- [Google Scholar]
- Opioid use following cervical spine surgery: trends and factors associated with long-term use. Spine J. 2018;18:1974-1981.
- [Google Scholar]
- Persistent opioid use after spine surgery: a prospective cohort study. Spine (Phila Pa 1976). 2021;46:1428-1435.
- [Google Scholar]
- Early ambulation decreases length of hospital stay, perioperative complications and improves functional outcomes in elderly patients undergoing surgery for correction of adult degenerative scoliosis. Spine (Phila Pa 1976). 2017;42:1420-1425.
- [Google Scholar]
- Prehabilitation and early rehabilitation after spinal surgery: randomized clinical trial. Clin Rehabil. 2010;24:137-148.
- [Google Scholar]
- Should patients walk from the postanesthesia care unit to the general ward after a lumbar discectomy? A randomized study. J Perianesth Nurs. 2014;29:377-384.
- [Google Scholar]
- The benefits of implementing an early mobility protocol in postoperative neurosurgical spine patients. Am J Nurs. 2018;118:46-53.
- [Google Scholar]
- Improvement in pain after lumbar spine surgery: the role of preoperative expectations of pain relief. Clin J Pain. 2017;33:93-98.
- [Google Scholar]
- Reductions in length of stay, narcotics use, and pain following implementation of an enhanced recovery after surgery program for 1- to 3-level lumbar fusion surgery. Neurosurg Focus. 2019;46:E4.
- [Google Scholar]
- Enhanced recovery after surgery protocol for lumbar spinal surgery with regional anesthesia: a retrospective review. Cureus. 2021;13
- [Google Scholar]
- Development of an Enhanced Recovery after Surgery (ERAS) approach for lumbar spinal fusion. J Neurosurg Spine. 2017;26:411-418.
- [Google Scholar]
- Diabetes is related to worse patient-reported outcomes at two years following spine surgery. J Bone Joint Surg Am. 2016;98:15-22.
- [Google Scholar]
- The impact of diabetes on the outcomes of surgical and nonsurgical treatment of patients in the spine patient outcomes research trial. Spine (Phila Pa 1976). 2011;36:290-307.
- [Google Scholar]
- Diabetes is associated with greater leg pain and worse patient-reported outcomes at 1 year after lumbar spine surgery. Sci Rep. 2021;11:8142.
- [Google Scholar]

